Globe Newswire (Thu, 25-Jun 4:01 PM ET)
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Wed, 24-Jun 10:33 PM ET)
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Globe Newswire (Wed, 24-Jun 4:01 PM ET)
Market Chameleon (Mon, 22-Jun 4:58 AM ET)
Globe Newswire (Mon, 22-Jun 8:00 AM ET)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 5-Jun 8:01 AM ET)
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 6-May 8:00 AM ET)
Globe Newswire (Wed, 29-Apr 8:00 AM ET)
Globe Newswire (Mon, 27-Apr 5:21 PM ET)
Market Chameleon (Thu, 2-Oct 5:54 AM ET)
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Taysha Gene Therapies trades on the NASDAQ stock market under the symbol TSHA.
As of July 8, 2026, TSHA stock price declined to $6.32 with 484,534 million shares trading.
TSHA has a beta of 2.52, meaning it tends to be more sensitive to market movements. TSHA has a correlation of 0.17 to the broad based SPY ETF.
TSHA has a market cap of $1.82 billion. This is considered a Small Cap stock.
Last quarter Taysha Gene Therapies reported $0 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-758,330 and missed earnings estimates by -$.02.
In the last 3 years, TSHA traded as high as $7.30 and as low as $.62.
The top ETF exchange traded funds that TSHA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
TSHA has outperformed the market in the last year with a return of +170.1%, while the SPY ETF gained +20.6%. In the last 3 month period, TSHA beat the market returning +38.3%, while SPY returned +12.7%. However, in the most recent 2 weeks TSHA has underperformed the stock market by returning -7.9%, while SPY returned +1.0%.
TSHA support price is $6.22 and resistance is $6.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TSHA shares will trade within this expected range on the day.
